{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:14:10Z","timestamp":1787494450804,"version":"build-2736575974"},"reference-count":192,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>\n                    Pompe disease (PD) is caused by the deficiency of the lysosomal enzyme acid \u03b1-glucosidase (GAA), resulting in systemic pathological glycogen accumulation. PD can present with cardiac, skeletal muscle, and central nervous system manifestations, as a continuum of phenotypes among two main forms: classical infantile-onset PD (IOPD) and late-onset PD (LOPD). IOPD is caused by severe GAA deficiency and presents at birth with cardiac hypertrophy, muscle hypotonia, and severe respiratory impairment, leading to premature death, if not treated. LOPD is characterized by levels of residual GAA activity up to \u223c20% of normal and presents both in children and adults with a varied severity of muscle weakness and motor and respiratory deficit. Enzyme replacement therapy (ERT), based on repeated intravenous (i.v.) infusions of recombinant human GAA (rhGAA), represents the only available treatment for PD. Upon more than 10 years from its launch, it is becoming evident that ERT can extend the life span of IOPD and stabilize disease progression in LOPD; however, it does not represent a cure for PD. The limited uptake of the enzyme in key affected tissues and the high immunogenicity of rhGAA are some of the hurdles that limit ERT efficacy. GAA gene transfer with adeno-associated virus (AAV) vectors has been shown to reduce glycogen storage and improve the PD phenotype in preclinical studies following different approaches. Here, we present an overview of the different gene therapy approaches for PD, focusing on\n                    <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                    gene transfer with AAV vectors and discussing the potential opportunities and challenges in developing safe and effective gene therapies for the disease. Based on emerging safety and efficacy data from clinical trials for other protein deficiencies,\n                    <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                    gene therapy with AAV vectors appears to have the potential to provide a therapeutically relevant, stable source of GAA enzyme, which could be highly beneficial in PD.\n                  <\/jats:p>","DOI":"10.1089\/hum.2019.109","type":"journal-article","created":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T08:34:59Z","timestamp":1562920499000},"page":"1245-1262","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":30,"title":["Gene Therapy for Pompe Disease: The Time is now"],"prefix":"10.1177","volume":"30","author":[{"given":"Pasqualina","family":"Colella","sequence":"first","affiliation":[{"name":"Genethon, Evry, France"},{"name":"Department of Pediatrics, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mingozzi","sequence":"additional","affiliation":[{"name":"Genethon, Evry, France"},{"name":"Spark Therapeutics, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,9,24]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61555-X"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.11.033"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0442-y"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2016.12.004"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0902534106"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.resp.2013.06.007"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.resp.2016.02.007"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1540\/jsmr.54.100"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2012.44"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.13740"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2011.00031"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2011.06.012"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-34"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000165979.46537.56"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2013.07.002"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e3181815994"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddu476"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20807"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2012.52"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31317"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/21675511.2015.1068978"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201606547"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.031209.093756"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)53985-5"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M404008200"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-0655-y"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002523"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2012.09.015"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8219-8"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000251268.41188.04"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2009.08.003"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94328"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067052"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2010.08.009"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2017.06.007"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.138"},{"issue":"1","key":"e_1_3_3_38_2","first-page":"114","article-title":"New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond","volume":"12","author":"Kishnani PS","year":"2014","unstructured":"Kishnani PS, , Beckemeyer AA. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond. Pediatr Endocrinol Rev, 2014; 12 Suppl 1:114\u2013124.","journal-title":"Pediatr Endocrinol Rev"},{"key":"e_1_3_3_39_2","first-page":"723","article-title":"Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues","volume":"23","author":"Wenk J","year":"1991","unstructured":"Wenk J, , Hille A, , von Figura K. Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues. Biochem Int, 1991; 23:723\u2013731.","journal-title":"Biochem Int"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.1511"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2006.08.009"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8417-1-6"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2017.11.046"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2012.01.019"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2015.53"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2012.04.027"},{"key":"e_1_3_3_47_2","first-page":"1","article-title":"Pompe disease treatment with twice a week high dose alglucoside alfa in a patient with severe dilated cardiomyopathy","volume":"16","author":"Landis JL","year":"2018","unstructured":"Landis JL, , Hyland H, , Kindel SJ, et al. Pompe disease treatment with twice a week high dose alglucoside alfa in a patient with severe dilated cardiomyopathy. Mol Genet Metab Rep, 2018; 16:1\u20134.","journal-title":"Mol Genet Metab Rep"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2017.12.435"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbiotec.2017.03.033"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.37"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125358"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.438663"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0693-2"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.02.017"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.06.023"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040776"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-017-1505-9"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2017.12.028"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2011.07.004"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-252874"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2014.102"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.2174\/1566523215666150630132253"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2012.250"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2017.146"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedneo.2013.03.009"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.10.078"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.30.19086"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam6375"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.016"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-8966(99)00117-0"},{"key":"e_1_3_3_71_2","first-page":"S41","volume-title":"WORLD Symposium","volume":"126","author":"Colella P","year":"2019","unstructured":"Colella P, , Sellier P, , Cagin U, et al. Latent TGF-\u03b2\u2013binding protein 4 modulates disease severity in the knock-out mouse model of Pompe disease. In: WORLD Symposium. Orlando, FL: MGaM, 2019; 126:S41."},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn292"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2015.7"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.96"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300100"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.305"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.01.006"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31666"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201707573"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-306761"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198602063140611"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.025"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200419205"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-278234"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1233158"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2014.13"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(02)90716-1"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.09.017"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1088547"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09328"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404588"},{"key":"e_1_3_3_92_2","first-page":"11","article-title":"Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives","author":"Naldini L.","year":"2019","unstructured":"Naldini L. Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives. EMBO Mol Med, 2019; 11.","journal-title":"EMBO Mol Med"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0020-9"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-010181"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407309"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708538"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708483"},{"key":"e_1_3_3_99_2","first-page":"1","volume-title":"CADTH Issues in Emerging Health Technologies","author":"Patel U","year":"2016","unstructured":"Patel U, , Boucher M, , de Leseleuc L, et al. Voretigene Neparvovec: An Emerging Gene Therapy for the Treatment of Inherited Blindness. In: CADTH Issues in Emerging Health Technologies. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health, 2016:1\u201311."},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddz148"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.172"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.76"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2016.08.003"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.11.8568-8577.1998"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.15.6969-6976.2001"},{"key":"e_1_3_3_106_2","unstructured":"Kuntz N Shieh P Smith B et al. Aspiro Phase 1\/2 Gene Therapy Trial in X-Linked Myotubular Myopathy (Xlmtm): Preliminary Safety and Efficacy Findings. Chicago: The American Society of Gene and Cell Therpay (ASGCT) 2018."},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.029"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2017.11.007"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-101416-041936"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddr174"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2002.0580"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.01.012"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.282"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2001.0441"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.2174\/1566523215666150630121750"},{"key":"e_1_3_3_116_2","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2015.068"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-306647"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.04.024"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.133"},{"key":"e_1_3_3_120_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2015.103"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2015.033"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200316887"},{"key":"e_1_3_3_123_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0847"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1086\/522236"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.063"},{"key":"e_1_3_3_126_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2016.12.010"},{"key":"e_1_3_3_127_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-588194"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-288001"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2008.010"},{"key":"e_1_3_3_130_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2014.18"},{"key":"e_1_3_3_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2017.12.011"},{"key":"e_1_3_3_132_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16105"},{"key":"e_1_3_3_133_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.02.004"},{"key":"e_1_3_3_134_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.07.011"},{"key":"e_1_3_3_135_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/10.19.2039"},{"key":"e_1_3_3_136_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.179"},{"key":"e_1_3_3_137_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108046"},{"key":"e_1_3_3_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2006.08.001"},{"key":"e_1_3_3_139_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.12-207472"},{"key":"e_1_3_3_140_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.06.52"},{"key":"e_1_3_3_141_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2016.83"},{"key":"e_1_3_3_142_2","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.1372"},{"key":"e_1_3_3_143_2","unstructured":"Puzzo F Cagin U Moya-Nilges M et al. Correction of Advanced Pompe Phenotype in Mice with AAV Liver Gene Transfer of Secretable GAA. Chicago: The American Society of Gene and Cell Therpay (ASGCT) 2018."},{"key":"e_1_3_3_144_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-018-0609-y"},{"key":"e_1_3_3_145_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-015-0243-x"},{"key":"e_1_3_3_146_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.197"},{"key":"e_1_3_3_147_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.183"},{"key":"e_1_3_3_148_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.151"},{"key":"e_1_3_3_149_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2013.233"},{"key":"e_1_3_3_150_2","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2016.119"},{"key":"e_1_3_3_151_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06621-3"},{"key":"e_1_3_3_152_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.11.002"},{"key":"e_1_3_3_153_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-017-0464-2"},{"key":"e_1_3_3_154_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-017-0763-4"},{"key":"e_1_3_3_155_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.02.013"},{"key":"e_1_3_3_156_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30169-2"},{"key":"e_1_3_3_157_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2013.238"},{"key":"e_1_3_3_158_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.09.001"},{"key":"e_1_3_3_159_2","first-page":"85","article-title":"Tandem promoter design confers tolerogenic and persistent transgene expression to AAV gene therapy in neonate Pompe mice","volume":"17","author":"Colella P","year":"2018","unstructured":"Colella P, , Sellier P, , Costa-Verdera H, et al. Tandem promoter design confers tolerogenic and persistent transgene expression to AAV gene therapy in neonate Pompe mice. Mol Ther Methods Clin Dev, 2018; 17:12:85\u2013101.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"e_1_3_3_160_2","first-page":"887","article-title":"Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II","volume":"56","author":"Boerkoel CF","year":"1995","unstructured":"Boerkoel CF, , Exelbert R, , Nicastri C, et al. Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. Am J Hum Genet, 1995; 56:887\u2013897.","journal-title":"Am J Hum Genet"},{"key":"e_1_3_3_161_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2017.03.001"},{"key":"e_1_3_3_162_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.05.019"},{"key":"e_1_3_3_163_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2017.03.002"},{"key":"e_1_3_3_164_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddp535"},{"key":"e_1_3_3_165_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.57"},{"key":"e_1_3_3_166_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn290"},{"key":"e_1_3_3_167_2","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201202176"},{"key":"e_1_3_3_168_2","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004754"},{"key":"e_1_3_3_169_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15352-2"},{"key":"e_1_3_3_170_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1358"},{"key":"e_1_3_3_171_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1549"},{"key":"e_1_3_3_172_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-181479"},{"key":"e_1_3_3_173_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617726114"},{"key":"e_1_3_3_174_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000228"},{"key":"e_1_3_3_175_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv451"},{"key":"e_1_3_3_176_2","unstructured":"Solid Biosciences Inc. Solid Biosciences Announces Clinical Hold on SGT-001 Phase I\/II Clinical Trial for Duchenne Muscular Dystrophy. 2018. https:\/\/www.globenewswire.com\/news-release\/2018\/03\/14\/1422770\/0\/en\/Solid-Biosciences-Announces-Clinical-Hold-On-SGT-001-Phase-I-II-Clinical-Trial-For-Duchenne-Muscular-Dystrophy.html (last accessed August29 2019)."},{"key":"e_1_3_3_177_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.02.005"},{"key":"e_1_3_3_178_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2017.10.005"},{"key":"e_1_3_3_179_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24437"},{"key":"e_1_3_3_180_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-015-0058-3"},{"key":"e_1_3_3_181_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158912"},{"key":"e_1_3_3_182_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31320"},{"key":"e_1_3_3_183_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0103-8"},{"key":"e_1_3_3_184_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2017.09.002"},{"key":"e_1_3_3_185_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2016.05.013"},{"key":"e_1_3_3_186_2","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2016.29"},{"key":"e_1_3_3_187_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073304"},{"key":"e_1_3_3_188_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0508685103"},{"key":"e_1_3_3_189_2","doi-asserted-by":"publisher","DOI":"10.2174\/156652309787909490"},{"key":"e_1_3_3_190_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1406674111"},{"key":"e_1_3_3_191_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.2AB0613-342RR"},{"key":"e_1_3_3_192_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.02.014"},{"key":"e_1_3_3_193_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2017.12.002"}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2019.109","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2019.109","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2019.109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:54:42Z","timestamp":1777449282000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2019.109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,24]]},"references-count":192,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1089\/hum.2019.109"],"URL":"https:\/\/doi.org\/10.1089\/hum.2019.109","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,24]]}}}